Aditxt (ADTX) Stock Price, News & Analysis

Company Overview

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Key Stats

• Today's Range: $0.96 to $1.03
• 50-Day Range: $0.99 to $1.70
• 52-Week Range: $0.96 to $21,400.00
• Volume: 234,755 shs
• Average Volume: 868,089 shs
• Market Capitalization: $2.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ADTX Stock Analysis - Frequently Asked Questions

How have ADTX shares performed this year?

Aditxt's stock was trading at $47.45 at the beginning of the year. Since then, ADTX shares have decreased by 97.9% and is now trading at $0.9875.

How were Aditxt's earnings last quarter?

Aditxt, Inc. (NASDAQ:ADTX) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($8.12) earnings per share for the quarter, beating analysts' consensus estimates of ($26,400.00) by $26,391.88. The business earned $0 million during the quarter, compared to analysts' expectations of $0.43 million. Aditxt had a negative net margin of 46,082.47% and a negative trailing twelve-month return on equity of 389.10%.

When did Aditxt's stock split?

Aditxt's stock reverse split on the morning of Monday, March 17th 2025.The 1-250 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 14th 2025. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

How do I buy shares of Aditxt?

Shares of ADTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aditxt own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aditxt investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Plug Power (PLUG), SNDL (SNDL), AMC Entertainment (AMC) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/05/2025
• Next Earnings (Estimated): 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ADTX
• CIK: 1726711
• Web: www.aditxt.com
• Phone: 650-870-1200
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.45 million
• Net Margins: -46,082.47%
• Pretax Margin: -47,309.48%
• Return on Equity: -389.10%
• Return on Assets: -84.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.08
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: $130 thousand
• Price / Sales: 16.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.52) per share
• Price / Book: -0.65

Miscellaneous

• Outstanding Shares: 2,120,000
• Free Float: 2,120,000
• Market Cap: $2.09 million
• Optionable: No Data
• Beta: 1.50